中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2014年
3期
248-251
,共4页
唐少文%施敏红%许珍林%陈茹%王晶%徐标
唐少文%施敏紅%許珍林%陳茹%王晶%徐標
당소문%시민홍%허진림%진여%왕정%서표
阿托伐他汀%动脉粥样硬化%Meta分析%颈动脉内膜中层厚度
阿託伐他汀%動脈粥樣硬化%Meta分析%頸動脈內膜中層厚度
아탁벌타정%동맥죽양경화%Meta분석%경동맥내막중층후도
Atorvastatin%Atherosclerosis%Meta-analysis%Carotid artery intima-media thickness
目的:系统评价中国动脉粥样硬化患者在常规治疗基础上加用阿托伐他汀后抗动脉粥样硬化治疗的疗效。方法采用计算机检索PubMed、EMBASE、CENTRAL、CBMDisc、CMCI、CNKI、VIP、Wanfang数据库中阿托伐他汀抗动脉粥样硬化的疗效的随机与半随机临床试验,两名评价者独立进行文献质量评价、提取资料并进行核对,运用Review manager 5.2.1软件分析均数差及95%可信区间。结果符合纳入标准文献共27篇,干预组总人数为1558人,对照组为1495人。Meta分析结果显示:与对照组比较,干预组使用阿托伐他汀10 mg/d治疗24周颈动脉内膜中膜厚度(IMT)值降低0.15 mm (95%CI:-0.30~-0.01),治疗96周IMT降低0.81 mm(95%CI:-1.11~-0.51);阿托伐他汀20 mg/d治疗12周能使颈动脉IMT值降低0.10 mm(95%CI:-0.18~-0.03),治疗24周颈动脉IMT值降低0.36 mm (95%CI:-0.49~-0.23),治疗48周颈动脉IMT值降低0.22 mm(95%CI:-0.31~-0.13)。结论阿托伐他汀有效降低颈动脉内膜中层的厚度,减缓动脉粥样硬化的进展。
目的:繫統評價中國動脈粥樣硬化患者在常規治療基礎上加用阿託伐他汀後抗動脈粥樣硬化治療的療效。方法採用計算機檢索PubMed、EMBASE、CENTRAL、CBMDisc、CMCI、CNKI、VIP、Wanfang數據庫中阿託伐他汀抗動脈粥樣硬化的療效的隨機與半隨機臨床試驗,兩名評價者獨立進行文獻質量評價、提取資料併進行覈對,運用Review manager 5.2.1軟件分析均數差及95%可信區間。結果符閤納入標準文獻共27篇,榦預組總人數為1558人,對照組為1495人。Meta分析結果顯示:與對照組比較,榦預組使用阿託伐他汀10 mg/d治療24週頸動脈內膜中膜厚度(IMT)值降低0.15 mm (95%CI:-0.30~-0.01),治療96週IMT降低0.81 mm(95%CI:-1.11~-0.51);阿託伐他汀20 mg/d治療12週能使頸動脈IMT值降低0.10 mm(95%CI:-0.18~-0.03),治療24週頸動脈IMT值降低0.36 mm (95%CI:-0.49~-0.23),治療48週頸動脈IMT值降低0.22 mm(95%CI:-0.31~-0.13)。結論阿託伐他汀有效降低頸動脈內膜中層的厚度,減緩動脈粥樣硬化的進展。
목적:계통평개중국동맥죽양경화환자재상규치료기출상가용아탁벌타정후항동맥죽양경화치료적료효。방법채용계산궤검색PubMed、EMBASE、CENTRAL、CBMDisc、CMCI、CNKI、VIP、Wanfang수거고중아탁벌타정항동맥죽양경화적료효적수궤여반수궤림상시험,량명평개자독립진행문헌질량평개、제취자료병진행핵대,운용Review manager 5.2.1연건분석균수차급95%가신구간。결과부합납입표준문헌공27편,간예조총인수위1558인,대조조위1495인。Meta분석결과현시:여대조조비교,간예조사용아탁벌타정10 mg/d치료24주경동맥내막중막후도(IMT)치강저0.15 mm (95%CI:-0.30~-0.01),치료96주IMT강저0.81 mm(95%CI:-1.11~-0.51);아탁벌타정20 mg/d치료12주능사경동맥IMT치강저0.10 mm(95%CI:-0.18~-0.03),치료24주경동맥IMT치강저0.36 mm (95%CI:-0.49~-0.23),치료48주경동맥IMT치강저0.22 mm(95%CI:-0.31~-0.13)。결론아탁벌타정유효강저경동맥내막중층적후도,감완동맥죽양경화적진전。
Objective To review systematically the curative effect of atorvastatin on atherosclerosis in patients with atherosclerosis treated with atorvastatin besides of routine treatment in China. Methods The databases of PubMed, EMBASE, CENTRAL, CBMDisc, CMCI, CNKI, VIP and WanFang were retrieved with computer for collecting the randomized or semi-randomized clinical trials about the curative effect of atorvastatin on atherosclerosis, and then 2 reviewers independently reviewed trial quality, extract material and checked data. The software of Review manager 5.2.1 was used for analyzing mean difference (MD) and 95%confidence interval (CI). Results There were totally 27 trials included involving 1558 cases in intervention group and 1495 cases in control group. The Meta-analysis showed that carotid artery intima-media thickness (CA-IMT) was reduced by 0.15 mm (95%CI:-0.30--0.01) after treatment with atorvastatin (10 mg/d) for 24 w, and by 0.81 mm (95%CI:-1.11--0.51) after 96 w in intervention group compared with control group. CA-IMT was reduced by 0.10 mm (95%CI:-0.18--0.03) after treatment with atorvastatin (20 mg/d) for 12 w, by 0.36 mm (95%CI:-0.49--0.23) after 24 w, and by 0.22 mm (95%CI:-0.31--0.13) after 48 w in intervention group compared with control group. Conclusion Atorvastatin can effectively reduce CA-IMT and delay the development of atherosclerosis.